175 related articles for article (PubMed ID: 8251895)
1. Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.
Shtalrid M; Lugassy G; Rosensaft J; Berrebi A
Leuk Lymphoma; 1993; 11 Suppl 1():193-7. PubMed ID: 8251895
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
Steegmann JL; Lavilla E; Somolinos N; Pérez-Sánchez M; Lamana M; Olmeda F; Cámara R; Arranz R; Ferro MT; Fernández-Rañada JM
Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
4. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
[TBL] [Abstract][Full Text] [Related]
5. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
[TBL] [Abstract][Full Text] [Related]
6. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Ph-positive chronic myeloid leukemia with alpha-interferon (ROFERON-A). The Italian Cooperative Study Group experience. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
Leuk Lymphoma; 1993; 11 Suppl 1():153-7. PubMed ID: 8251889
[TBL] [Abstract][Full Text] [Related]
8. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
10. Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.
Alimena G; Meloni G; de Cuia MR; Rondinelli MB; Lo Coco F; Montefusco E; Mancini M; Pinto R; Nanni M; Cedrone M
Leuk Lymphoma; 1993; 11 Suppl 1():281-91. PubMed ID: 7902746
[TBL] [Abstract][Full Text] [Related]
11. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C
Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890
[TBL] [Abstract][Full Text] [Related]
12. Interferon alpha 2A in the treatment of chronic myelogenous leukemia in chronic phase. Results of the Spanish Group.
Fernandez-Rañada JM; Lavilla E; Odriozola J; Garcia-Laraña J; Lozano M; Parody R; Giraldo MP; Carbonell F; Ferro MT; Steegmann JL
Leuk Lymphoma; 1993; 11 Suppl 1():175-9. PubMed ID: 8251892
[TBL] [Abstract][Full Text] [Related]
13. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
14. A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.
Talpaz M; Kurzrock R; Kantarjian H; Rothberg J; Saks S; Evans L; Gutterman JU
Cancer; 1991 Nov; 68(10):2125-30. PubMed ID: 1913450
[TBL] [Abstract][Full Text] [Related]
15. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Schaefer UW
Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
[TBL] [Abstract][Full Text] [Related]
16. A multicentric randomised study of alpha 2b interferon (IFN) and hydroxyurea (HU) with or without cytosine-arabinoside (Ara-c) in previously untreated patients with Ph+ chronic myelocytic leukemia (CML): preliminary cytogenetic results.
Guilhot F; Abgrall JF; Harousseau JL; Bauters F; Brice P; Dine G; Tilly H; Ifrah N; Cassasus P; Rochant H
Leuk Lymphoma; 1993; 11 Suppl 1():181-3. PubMed ID: 8251893
[TBL] [Abstract][Full Text] [Related]
17. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
[TBL] [Abstract][Full Text] [Related]
18. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
Bonifazi F; de Vivo A; Rosti G; Guilhot F; Guilhot J; Trabacchi E; Hehlmann R; Hochhaus A; Shepherd PC; Steegmann JL; Kluin-Nelemans HC; Thaler J; Simonsson B; Louwagie A; Reiffers J; Mahon FX; Montefusco E; Alimena G; Hasford J; Richards S; Saglio G; Testoni N; Martinelli G; Tura S; Baccarani M; ; ; ; ; ; ; ;
Blood; 2001 Nov; 98(10):3074-81. PubMed ID: 11698293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
